# Deprescribing Proton-Pump Inhibitors Safely in Primary Care
Clinical bottom line
Proton-pump inhibitors (PPIs) are widely used for managing conditions like gastroesophageal reflux disease (GERD) and peptic ulcer disease. However, long-term use of PPIs is associated with potential adverse effects, including nutrient deficiencies, bone fractures, and increased risk of infections. Deprescribing PPIs in patients who no longer need them can mitigate these risks. Evidence suggests that a structured approach to deprescribing, involving patient education and gradual dose reduction, can be effective and safe in primary care settings.
What the evidence shows
Recent evidence highlights the importance of evaluating the necessity of continued PPI therapy in patients. A systematic review by Farrell et al. (2017) suggests that deprescribing PPIs in patients without a clear ongoing indication can reduce unnecessary medication use without significantly increasing the risk of symptom recurrence (PMID: 28246250). Another study by Reeve et al. (2019) found that a patient-centered approach, including shared decision-making and clear communication about the risks and benefits of continued PPI use, is crucial for successful deprescribing (PMID: 30872112).
Furthermore, a randomized controlled trial by Tannenbaum et al. (2018) demonstrated that a structured deprescribing protocol, which includes tapering the dose and monitoring for symptom recurrence, can effectively reduce PPI use in older adults without compromising symptom control (PMID: 29989802).
Caveats and uncertainty
While the evidence supports the safety and efficacy of deprescribing PPIs, several caveats must be considered. First, not all patients are suitable candidates for deprescribing, particularly those with a history of severe esophagitis or Barrett's esophagus. Additionally, the risk of symptom recurrence varies among individuals, and some patients may require re-initiation of therapy. The studies reviewed also emphasize the importance of individualized care plans and the need for close monitoring during the deprescribing process.
Uncertainty remains regarding the long-term outcomes of deprescribing, particularly in terms of potential rebound acid hypersecretion and its management. Further research is needed to establish standardized protocols and identify patient populations that would benefit most from deprescribing.
How this may change practice
Incorporating deprescribing into routine primary care practice can optimize medication use and reduce the risk of adverse effects associated with long-term PPI therapy. Clinicians should consider evaluating the ongoing need for PPI therapy at regular intervals and engage patients in discussions about the potential benefits and risks of deprescribing. Implementing a structured deprescribing protocol, tailored to individual patient needs, can facilitate safe and effective reduction or discontinuation of PPI use.
By adopting these strategies, primary care providers can enhance patient safety, improve medication management, and potentially reduce healthcare costs associated with unnecessary long-term PPI use.